🔎 Trials Near Me

Home › Glioma › District of Columbia

Pag-aaral pangklinika para sa Glioma sa District of Columbia

14 pag-aaral para sa Glioma ang naghahanap ng mga kalahok sa mga site sa District of Columbia.

Mga Lungsod sa District of Columbia

Opisyal na teksto ng pag-aaral (English)

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 1/2
12 Months – 21 Years · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05099003

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  • Johns Hopkins Sibley Memorial Hospital, Washington D.C.
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07326566

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 2
12 Months – 39 Years · Lahat ng kasarian · Na-update Set 21, 2026 · NCT06838676

NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors

  • Children's National Hospital, Washington D.C.
Nagre-recruitPhase 1
Edad 3 hanggang 25 · Lahat ng kasarian · Na-update Set 9, 2026 · NCT07664176

Targeted Pediatric High-Grade Glioma Therapy

  • Children's National Medical Center, Washington D.C.
Nagre-recruitObservasyonal na pag-aaral
12 Months – 39 Years · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05839379

Study of Olutasidenib and Temozolomide in HGG

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT06161974

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 2
Edad 3 hanggang 39 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05096481

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 1
Edad 1 hanggang 25 · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT04485559

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

  • Children's National Hospital, Washington D.C.
Nagre-recruitPhase 1/2
Edad 1 hanggang 26 · Lahat ng kasarian · Na-update Hul 10, 2026 · NCT06712875

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Children's National Medical Center, Washington D.C.
Nagre-recruitMaagang Phase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT06333899

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

  • Children's National Hospital, Washington D.C.
Nagre-recruitPhase 1
Edad 4 pataas · Lahat ng kasarian · Na-update Hun 25, 2026 · NCT04573140

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Children's National Medical Center, Washington D.C.
Nagre-recruitPhase 2
12 Months – 39 Years · Lahat ng kasarian · Na-update May 29, 2026 · NCT05843253

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • Sibley Memorial Hospital, Washington D.C.
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2026 · NCT06810544

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

  • Children's National Medical Center, Washington D.C.
Nagre-recruitMaagang Phase 1
Hanggang edad 21 · Lahat ng kasarian · Na-update Mar 18, 2026 · NCT04655404

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.